View Item 

Show simple item record

Should Patients with High‐Risk Soft Tissue Sarcoma Receive Adjuvant Chemotherapy?
dc.contributor.authorSchuetze, Scott M.
dc.contributor.authorPatel, Shreyaskumar
dc.date.accessioned2017-12-15T16:47:22Z
dc.date.available2017-12-15T16:47:22Z
dc.date.issued2009-10
dc.identifier.citationSchuetze, Scott M.; Patel, Shreyaskumar (2009). "Should Patients with High‐Risk Soft Tissue Sarcoma Receive Adjuvant Chemotherapy?." The Oncologist 14(10): 1003-1012.
dc.identifier.issn1083-7159
dc.identifier.issn1549-490X
dc.identifier.urihttps://hdl.handle.net/2027.42/139941
dc.publisherAlphaMed Press
dc.publisherWiley Periodicals, Inc.
dc.subject.otherAdjuvant
dc.subject.otherSoft tissue sarcoma
dc.subject.otherNeoadjuvant
dc.subject.otherChemotherapy
dc.titleShould Patients with High‐Risk Soft Tissue Sarcoma Receive Adjuvant Chemotherapy?
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelHematology and Oncology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumaUniversity of Michigan, Ann Arbor Michigan, USA;
dc.contributor.affiliationotherbMD Anderson Cancer Center, University of Texas, Houston, Texas, USA
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139941/1/onco1003.pdf
dc.identifier.doi10.1634/theoncologist.2009-0007
dc.identifier.sourceThe Oncologist
dc.identifier.citedreferenceCormier JN, Huang X, Xing Y et al. Cohort analysis of patients with localized, high‐risk, extremity soft tissue sarcoma treated at two cancer centers: Chemotherapy‐associated outcomes J Clin Oncol 2004 22 4567 – 4574
dc.identifier.citedreferenceFrustaci S, Gherlinzoni F, De Paoli A et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: Results of the Italian randomized cooperative trial J Clin Oncol 2001 19 1238 – 1247
dc.identifier.citedreferenceFrustaci S, De Paoli A, Bidoli E et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas Oncology 2003 65 suppl 2 80 – 84
dc.identifier.citedreferencePetrioli R, Coratti A, Correale P et al. Adjuvant epirubicin with or without ifosfamide for adult soft‐tissue sarcoma Am J Clin Oncol 2002 25 468 – 473
dc.identifier.citedreferenceBrodowicz T, Schwameis E, Widder J et al. Intensified adjuvant IFADIC chemotherapy for adult soft tissue sarcoma: A prospective randomized feasibility trial Sarcoma 2000 4 151 – 160
dc.identifier.citedreferenceGortzak E, Azzarelli A, Buesa J et al. A randomised phase II study on neo‐adjuvant chemotherapy for ‘high‐risk’ adult soft‐tissue sarcoma Eur J Cancer 2001 37 1096 – 1103
dc.identifier.citedreferenceGrobmyer SR, Maki RG, Demetri GD et al. Neo‐adjuvant chemotherapy for primary high‐grade extremity soft tissue sarcoma Ann Oncol 2004 15 1667 – 1672
dc.identifier.citedreferenceEilber FC, Brennan MF, Eilber FR et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma Ann Surg 2007 246 105 – 113
dc.identifier.citedreferenceEilber FC, Eilber FR, Eckardt J et al. The impact of chemotherapy on the survival of patients with high‐grade primary extremity liposarcoma Ann Surg 2004 240 686 – 695 discussion 695–697
dc.identifier.citedreferenceDeLaney TF, Spiro IJ, Suit HD et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft‐tissue sarcomas Int J Radiat Oncol Biol Phys 2003 56 1117 – 1127
dc.identifier.citedreferenceKraybill WG, Harris J, Spiro IJ et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high‐risk, high‐grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514 J Clin Oncol 2006 24 619 – 625
dc.identifier.citedreferenceEilber FC, Rosen G, Eckardt J et al. Treatment‐induced pathologic necrosis: A predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high‐grade extremity soft tissue sarcomas J Clin Oncol 2001 19 3203 – 3209
dc.identifier.citedreferenceSchuetze SM, Rubin BP, Vernon C et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy Cancer 2005 103 339 – 348
dc.identifier.citedreferenceIssels RD, Abdel‐Rahman S, Wendtner C et al. Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high‐risk adult soft‐tissue sarcomas (STS) of adults: Long‐term results of a phase II study Eur J Cancer 2001 37 1599 – 1608
dc.identifier.citedreferenceEilber F, Giuliano A, Eckardt J et al. Adjuvant chemotherapy for osteosarcoma: A randomized prospective trial J Clin Oncol 1987 5 21 – 26
dc.identifier.citedreferenceLink MP, Goorin AM, Miser AW et al. The effect of adjuvant chemotherapy on relapse‐free survival in patients with osteosarcoma of the extremity N Engl J Med 1986 314 1600 – 1606
dc.identifier.citedreferenceNesbit ME Jr, Gehan EA, Burgert EO Jr et al. Multimodal therapy for the management of primary, nonmetastatic Ewing’s sarcoma of bone: A long‐term follow‐up of the First Intergroup study J Clin Oncol 1990 8 1664 – 1674
dc.identifier.citedreferenceGrier HE, Krailo MD, Tarbell NJ et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone N Engl J Med 2003 348 694 – 701
dc.identifier.citedreferenceEarly Breast Cancer Trialists’ Collaborative Group (EBCTCG) Clarke M, Coates AS, Darby SC et al. Adjuvant chemotherapy in oestrogen‐receptor‐poor breast cancer: Patient‐level meta‐analysis of randomised trials Lancet 2008 371 29 – 40
dc.identifier.citedreferenceCarlson RW, McCormick B Update: NCCN breast cancer clinical practice guidelines J Natl Compr Canc Netw 2005 3 suppl 1 S7 – S11
dc.identifier.citedreferenceBlay JY, Le Cesne A Adjuvant chemotherapy in localized soft tissue sarcomas: Still not proven The Oncologist 2009 14 1013 – 1020
dc.identifier.citedreferenceCDM Fletcher, KK Unni, F Mertens, eds. Pathology and Genetics of Tumours of Soft Tissue and Bone, Lyon, France: IARC Press, 2002, 427.
dc.identifier.citedreferenceBhangu AA, Beard JA, Grimer RJ Should soft tissue sarcomas be treated at a specialist centre? Sarcoma 2004 8 1 – 6
dc.identifier.citedreferenceJemal A, Siegel R, Ward E et al. Cancer statistics, 2009 CA Cancer J Clin 2009 59 225 – 249
dc.identifier.citedreferenceLAG Reis, D Harkins, M Krapcho, et al. SEER Cancer Statistics Review, 1975–2004, Bethesda, MD: National Cancer Institute, 2007 accessed December 31, 2008 Available at http://seer.cancer.gov/csr/1975_2004/.
dc.identifier.citedreferenceCoindre JM, Terrier P, Bui NB et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group J Clin Oncol 1996 14 869 – 877
dc.identifier.citedreferencePisters PW, Leung DH, Woodruff J et al. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities J Clin Oncol 1996 14 1679 – 1689
dc.identifier.citedreferenceStefanovski PD, Bidoli E, De Paoli A et al. Prognostic factors in soft tissue sarcomas: A study of 395 patients Eur J Surg Oncol 2002 28 153 – 164
dc.identifier.citedreferenceWeitz J, Antonescu CR, Brennan MF Localized extremity soft tissue sarcoma: Improved knowledge with unchanged survival over time J Clin Oncol 2003 21 2719 – 2725
dc.identifier.citedreferenceBenjamin RS, Wiernik PH, Bachur NR Adriamycin: A new effective agent in the therapy of disseminated sarcomas Med Pediatr Oncol 1975 1 63 – 76
dc.identifier.citedreferenceO’Bryan RM, Luce JK, Talley RW et al. Phase II evaluation of adriamycin in human neoplasia Cancer 1973 32 1 – 8
dc.identifier.citedreferenceEdmonson JH, Ryan LM, Blum RH et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas J Clin Oncol 1993 11 1269 – 1275
dc.identifier.citedreferenceRosenberg SA, Tepper J, Glatstein E et al. Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities Cancer 1983 52 424 – 434
dc.identifier.citedreferenceGherlinzoni F, Bacci G, Picci P et al. A randomized trial for the treatment of high‐grade soft‐tissue sarcomas of the extremities: Preliminary observations J Clin Oncol 1986 4 552 – 558
dc.identifier.citedreferenceA Ravaud, BN Bui, J Coindre, et al. Adjuvant chemotherapy with cyvadic in high risk soft tissue sarcoma: A randomized prospective trial. In SE Salmon, ed. Adjuvant Therapy of Cancer, Philadelphia: WB Saunders, 1990; VI, 556 – 566.
dc.identifier.citedreferenceAntman K, Suit H, Amato D et al. Preliminary results of a randomized trial of adjuvant doxorubicin for sarcomas: Lack of apparent difference between treatment groups J Clin Oncol 1984 2 601 – 608
dc.identifier.citedreferenceTierney JF, Mosseri V, Stewart LA et al. Adjuvant chemotherapy for soft‐tissue sarcoma: Review and meta‐analysis of the published results of randomised clinical trials Br J Cancer 1995 72 469 – 475
dc.identifier.citedreferenceMM Zalupski, JR Ryan, ME Hussein, et al. Defining the role of adjuvant chemotherapy for patients with soft tissue sarcoma of the extremities. In SE Salmon, ed. Adjuvant Therapy of Cancer, Philadelphia: JB Lippincott, 1993; VII, 385 – 392.
dc.identifier.citedreferenceAdjuvant chemotherapy for localised resectable soft‐tissue sarcoma of adults: Meta‐analysis of individual data. Sarcoma Meta‐Analysis Collaboration Lancet 1997 350 1647 – 1654
dc.identifier.citedreferencePervaiz N, Colterjohn N, Farrokhyar F et al. A systematic meta‐analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft‐tissue sarcoma Cancer 2008 113 573 – 581
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
onco1003.pdf
Size:
86.33KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.